Copyright
©The Author(s) 2016.
World J Hepatol. Jun 28, 2016; 8(18): 770-778
Published online Jun 28, 2016. doi: 10.4254/wjh.v8.i18.770
Published online Jun 28, 2016. doi: 10.4254/wjh.v8.i18.770
Figure 4 Forest plot for 1-year progression-free survival after yttrium-90 radioembolization and transarterial chemoembolization.
Y90RE showed a statistically significant benefit in terms of higher progression-free survival rate assessed at 1 year (OR = 1.67, 1.10-2.55, P = 0.02). There was no evidence of heterogeneity among individual studies (P = 0.66; I2 = 0%). Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; OR: Odds ratio.
- Citation: Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol 2016; 8(18): 770-778
- URL: https://www.wjgnet.com/1948-5182/full/v8/i18/770.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i18.770